Cargando…
A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
AIMS/INTRODUCTION: The aim of the present prospective observational study was to assess long‐term efficacy and safety of insulin degludec as a part of a basal–bolus therapy for Japanese patients with type 1 or type 2 diabetes in routine clinical practice. MATERIALS AND METHODS: In the present study,...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009132/ https://www.ncbi.nlm.nih.gov/pubmed/27181264 http://dx.doi.org/10.1111/jdi.12496 |
| _version_ | 1782451477513502720 |
|---|---|
| author | Shimoda, Seiya Sato, Miki Sekigami, Taiji Motoshima, Hiroyuki Yoshimura, Ryohei Fukuda, Kazuki Matsuo, Yasuto Noda, Hideyuki Okubo, Mina Ichimori, Shinji Fujisawa, Kazuo Fukunaga, Makiko Araki, Eiichi Nishikawa, Takeshi Furukawa, Noboru Matsumura, Takeshi Kondo, Tatsuya Kawashima, Junji Senokuchi, Takafumi Igata, Motoyuki Nishida, Kenro Yano, Tomohiko Taguchi, Tetsuya Matsuda, Hirofumi Tsuruzoe, Kaku Hirashima, Yoshiaki Kaneko, Kengo Kitanao, Sayaka Hazekawa, Iwaho Ebihara, Kenji Murata, Yusuke Watanabe, Eiichiro Ishii, Norio Nishioka, Hiroko Horio, Kaori Furusho, Masatsugu Ikema, Michiko Otsu, Kae Yano, Tomomi Shirao, Tomohiro Matsuyama, Rina Nishiyama, Toshihiko Matsuyoshi, Akiko Takeda, Haruo Kasho, Masaya Tsutsumi, Etsuro Ono, Kaoru |
| author_facet | Shimoda, Seiya Sato, Miki Sekigami, Taiji Motoshima, Hiroyuki Yoshimura, Ryohei Fukuda, Kazuki Matsuo, Yasuto Noda, Hideyuki Okubo, Mina Ichimori, Shinji Fujisawa, Kazuo Fukunaga, Makiko Araki, Eiichi Nishikawa, Takeshi Furukawa, Noboru Matsumura, Takeshi Kondo, Tatsuya Kawashima, Junji Senokuchi, Takafumi Igata, Motoyuki Nishida, Kenro Yano, Tomohiko Taguchi, Tetsuya Matsuda, Hirofumi Tsuruzoe, Kaku Hirashima, Yoshiaki Kaneko, Kengo Kitanao, Sayaka Hazekawa, Iwaho Ebihara, Kenji Murata, Yusuke Watanabe, Eiichiro Ishii, Norio Nishioka, Hiroko Horio, Kaori Furusho, Masatsugu Ikema, Michiko Otsu, Kae Yano, Tomomi Shirao, Tomohiro Matsuyama, Rina Nishiyama, Toshihiko Matsuyoshi, Akiko Takeda, Haruo Kasho, Masaya Tsutsumi, Etsuro Ono, Kaoru |
| author_sort | Shimoda, Seiya |
| collection | PubMed |
| description | AIMS/INTRODUCTION: The aim of the present prospective observational study was to assess long‐term efficacy and safety of insulin degludec as a part of a basal–bolus therapy for Japanese patients with type 1 or type 2 diabetes in routine clinical practice. MATERIALS AND METHODS: In the present study, 93 type 1 diabetes patients and 135 type 2 diabetes patients treated with insulin glargine or detemir were switched from their basal insulin to insulin degludec. The primary end‐points were the changes in glycated hemoglobin (HbA1c) from baseline at 3, 6 and 12 months. The secondary end‐points were changes in body mass index, insulin dose, frequency of hypoglycemia and adverse events. RESULTS: HbA1c levels from baseline were significantly reduced at 3, 6, and 12 months by 0.4, 0.4 and 0.3% in type 1 diabetes patients, respectively, and by 0.5, 0.5 and 0.3% in type 2 diabetes patients, respectively. Body mass index in type 1 diabetes patients increased significantly (P < 0.05), whereas that in type 2 diabetes patients did not change. Basal insulin dose decreased significantly at 3 months after switching (P < 0.05), and returned baseline dose at 12 months in type 1 diabetes and type 2 diabetes patients. The frequency of both total and nocturnal hypoglycemia decreased significantly in type 1 diabetes and type 2 diabetes patients (P < 0.05). The result of multiple regression analysis showed that baseline HbA1c was a significant independent variable of the percentage change in HbA1c with switching. CONCLUSION: In both type 1 diabetes and type 2 diabetes patients, switching from insulin glargine or insulin detemir to insulin degludec led to improvement of glycemic control with a significant reduction of hypoglycemia. |
| format | Online Article Text |
| id | pubmed-5009132 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-50091322016-09-12 A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) Shimoda, Seiya Sato, Miki Sekigami, Taiji Motoshima, Hiroyuki Yoshimura, Ryohei Fukuda, Kazuki Matsuo, Yasuto Noda, Hideyuki Okubo, Mina Ichimori, Shinji Fujisawa, Kazuo Fukunaga, Makiko Araki, Eiichi Nishikawa, Takeshi Furukawa, Noboru Matsumura, Takeshi Kondo, Tatsuya Kawashima, Junji Senokuchi, Takafumi Igata, Motoyuki Nishida, Kenro Yano, Tomohiko Taguchi, Tetsuya Matsuda, Hirofumi Tsuruzoe, Kaku Hirashima, Yoshiaki Kaneko, Kengo Kitanao, Sayaka Hazekawa, Iwaho Ebihara, Kenji Murata, Yusuke Watanabe, Eiichiro Ishii, Norio Nishioka, Hiroko Horio, Kaori Furusho, Masatsugu Ikema, Michiko Otsu, Kae Yano, Tomomi Shirao, Tomohiro Matsuyama, Rina Nishiyama, Toshihiko Matsuyoshi, Akiko Takeda, Haruo Kasho, Masaya Tsutsumi, Etsuro Ono, Kaoru J Diabetes Investig Articles AIMS/INTRODUCTION: The aim of the present prospective observational study was to assess long‐term efficacy and safety of insulin degludec as a part of a basal–bolus therapy for Japanese patients with type 1 or type 2 diabetes in routine clinical practice. MATERIALS AND METHODS: In the present study, 93 type 1 diabetes patients and 135 type 2 diabetes patients treated with insulin glargine or detemir were switched from their basal insulin to insulin degludec. The primary end‐points were the changes in glycated hemoglobin (HbA1c) from baseline at 3, 6 and 12 months. The secondary end‐points were changes in body mass index, insulin dose, frequency of hypoglycemia and adverse events. RESULTS: HbA1c levels from baseline were significantly reduced at 3, 6, and 12 months by 0.4, 0.4 and 0.3% in type 1 diabetes patients, respectively, and by 0.5, 0.5 and 0.3% in type 2 diabetes patients, respectively. Body mass index in type 1 diabetes patients increased significantly (P < 0.05), whereas that in type 2 diabetes patients did not change. Basal insulin dose decreased significantly at 3 months after switching (P < 0.05), and returned baseline dose at 12 months in type 1 diabetes and type 2 diabetes patients. The frequency of both total and nocturnal hypoglycemia decreased significantly in type 1 diabetes and type 2 diabetes patients (P < 0.05). The result of multiple regression analysis showed that baseline HbA1c was a significant independent variable of the percentage change in HbA1c with switching. CONCLUSION: In both type 1 diabetes and type 2 diabetes patients, switching from insulin glargine or insulin detemir to insulin degludec led to improvement of glycemic control with a significant reduction of hypoglycemia. John Wiley and Sons Inc. 2016-03-19 2016-09 /pmc/articles/PMC5009132/ /pubmed/27181264 http://dx.doi.org/10.1111/jdi.12496 Text en © 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Articles Shimoda, Seiya Sato, Miki Sekigami, Taiji Motoshima, Hiroyuki Yoshimura, Ryohei Fukuda, Kazuki Matsuo, Yasuto Noda, Hideyuki Okubo, Mina Ichimori, Shinji Fujisawa, Kazuo Fukunaga, Makiko Araki, Eiichi Nishikawa, Takeshi Furukawa, Noboru Matsumura, Takeshi Kondo, Tatsuya Kawashima, Junji Senokuchi, Takafumi Igata, Motoyuki Nishida, Kenro Yano, Tomohiko Taguchi, Tetsuya Matsuda, Hirofumi Tsuruzoe, Kaku Hirashima, Yoshiaki Kaneko, Kengo Kitanao, Sayaka Hazekawa, Iwaho Ebihara, Kenji Murata, Yusuke Watanabe, Eiichiro Ishii, Norio Nishioka, Hiroko Horio, Kaori Furusho, Masatsugu Ikema, Michiko Otsu, Kae Yano, Tomomi Shirao, Tomohiro Matsuyama, Rina Nishiyama, Toshihiko Matsuyoshi, Akiko Takeda, Haruo Kasho, Masaya Tsutsumi, Etsuro Ono, Kaoru A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) |
| title | A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) |
| title_full | A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) |
| title_fullStr | A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) |
| title_full_unstemmed | A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) |
| title_short | A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study) |
| title_sort | 1‐year, prospective, observational study of japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (kumamoto insulin degludec observational study) |
| topic | Articles |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009132/ https://www.ncbi.nlm.nih.gov/pubmed/27181264 http://dx.doi.org/10.1111/jdi.12496 |
| work_keys_str_mv | AT shimodaseiya a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT satomiki a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT sekigamitaiji a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT motoshimahiroyuki a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT yoshimuraryohei a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT fukudakazuki a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsuoyasuto a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nodahideyuki a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT okubomina a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ichimorishinji a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT fujisawakazuo a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT fukunagamakiko a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT arakieiichi a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishikawatakeshi a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT furukawanoboru a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsumuratakeshi a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kondotatsuya a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kawashimajunji a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT senokuchitakafumi a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT igatamotoyuki a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishidakenro a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT yanotomohiko a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT taguchitetsuya a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsudahirofumi a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT tsuruzoekaku a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT hirashimayoshiaki a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kanekokengo a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kitanaosayaka a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT hazekawaiwaho a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ebiharakenji a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT muratayusuke a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT watanabeeiichiro a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ishiinorio a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishiokahiroko a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT horiokaori a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT furushomasatsugu a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ikemamichiko a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT otsukae a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT yanotomomi a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT shiraotomohiro a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsuyamarina a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishiyamatoshihiko a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsuyoshiakiko a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT takedaharuo a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kashomasaya a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT tsutsumietsuro a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT onokaoru a1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT shimodaseiya 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT satomiki 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT sekigamitaiji 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT motoshimahiroyuki 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT yoshimuraryohei 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT fukudakazuki 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsuoyasuto 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nodahideyuki 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT okubomina 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ichimorishinji 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT fujisawakazuo 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT fukunagamakiko 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT arakieiichi 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishikawatakeshi 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT furukawanoboru 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsumuratakeshi 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kondotatsuya 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kawashimajunji 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT senokuchitakafumi 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT igatamotoyuki 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishidakenro 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT yanotomohiko 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT taguchitetsuya 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsudahirofumi 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT tsuruzoekaku 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT hirashimayoshiaki 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kanekokengo 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kitanaosayaka 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT hazekawaiwaho 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ebiharakenji 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT muratayusuke 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT watanabeeiichiro 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ishiinorio 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishiokahiroko 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT horiokaori 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT furushomasatsugu 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT ikemamichiko 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT otsukae 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT yanotomomi 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT shiraotomohiro 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsuyamarina 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT nishiyamatoshihiko 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT matsuyoshiakiko 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT takedaharuo 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT kashomasaya 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT tsutsumietsuro 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy AT onokaoru 1yearprospectiveobservationalstudyofjapaneseoutpatientswithtype1andtype2diabetesswitchingfrominsulinglargineordetemirtoinsulindegludecinbasalbolusinsulintherapykumamotoinsulindegludecobservationalstudy |